3-(2-氯苯基)丙酰氯 | 52085-97-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(2-氯苯基)丙酰氯
• 英文名称: 3-(2-chlorophenyl)propionyl chloride
• 英文别名: 3-(2-chlorophenyl)propanoyl chloride；2-Chlorobenzenepropanoyl chloride
• CAS: 52085-97-9
• 化学式: C₉H₈Cl₂O
• 分子量: 203.068
• InChiKey: QOQYBKQKBZOSAK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-(2-氯苯基)丙酰氯 在 rhodium(II) acetate dimer 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 生成 5-氯-3,4-二氢-1H-2-萘酮
  参考文献：
  名称：

  Structure–Activity relationship of linear peptide Bu-His-DPhe-Arg-Trp-Gly-NH2 at the human melanocortin-1 and -4 receptors: histidine substitution

  摘要：

  Systematic substitution of His(6) residue using non-selective hMC4R pentapeptide agonist (Bu-His(6)-DPhe(7)-Arg(8)-Trp(9)-Gly(10)- NH2) as the template led to the identification of Bu-Atc(6)(2-aminotetraline-2-carboxylic acid)-DPhe(7)-Arg(8)-Trp(9)-Gly(10)-NH2 which showed moderate selectivity towards hMC4R over hMC1R. Further SAR studies resulted in the discovery of Penta-5-BrAtc(6)-DPhe(7)-Arg(8)-Trp(9)-Gly(10)-NH2 and Penta-5-Me(2)NMAtc(6)-DPhe(7)-Arg(8)-Trp(9)-Gly(10)-NH2 which are potent hMC4R agonists and are inactive in hMC1R, hMC3R and hMC5R agonist assays. (C) 2002 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(02)00830-2
• 作为产物：
  描述：

  邻氯肉桂酸 在 草酰氯 、 palladium on activated charcoal 、 氢气 作用下， 生成 3-(2-氯苯基)丙酰氯
  参考文献：
  名称：

  Cyclohexyl-Fused, Spirobiindane-Derived, Phosphine-Catalyzed Synthesis of Tricyclic γ-Lactams and Kinetic Resolution of γ-Substituted Allenoates

  摘要：

  A C-2-symmetric chiral phosphine catalyst, NUSIOC-Phos, which can be easily derived from cyclohexyl-fused spirobiindane, was introduced. A highly enantioselective domino process involving pyrrolidine-2,3-diones and gamma-substituted allenoates catalyzed by NUSIOC-Phos has been disclosed. Diastereospecific tricyclic gamma-lactams containing five contiguous stereogenic centers were obtained in high yields and with nearly perfect enantioselectivities. A kinetic resolution process of racemic gamma-substituted allenoates was developed for the generation of optically enriched chiral allenoates.

  DOI：

  10.1021/jacs.9b07418

文献信息

• Aryloxyacetic Acid Diuretics with Uricosuric Activity. II. Substituted ((4-Oxo-4H-1-benzopyran-7-yl)oxy)acetic Acids and the Related Compounds.
  作者：Masayuki KITAGAWA、Kenjiro YAMAMOTO、Shinichi KATAKURA、Hideyuki KANNO、Koji YAMADA、Takayasu NAGAHARA、Makoto TANAKA

  DOI：10.1248/cpb.39.2681

  日期：——

  )oxy]acetic acids, and 4-oxo-3-phenyl-4H-furo[2,3-h]-[1]benzopyran-8-carboxylic acid were synthesized and tested for natriuretic and uricosuric activities. Among the compounds tested, 3,5-disubstituted [(4-oxo-4H-1-benzopyran-7-yl)oxy]acetic acids (6c-f, h, n and x) showed potent natriuretic and uricosuric activities, whereas 4-oxo-3-phenyl-4H-furo[2,3-h][1]benzopyran-8-carboxylic acid (6dd) possessed

  二和三取代的[（4-氧代-4H-1-苯并吡喃-7-基）氧基]乙酸和4-氧代-3-苯基-4H-呋喃[2,3-h]-[1]合成了苯并吡喃-8-羧酸，并测试了其利尿钠和尿尿排尿活性。在测试的化合物中，3,5-二取代的[（4-oxo-4H-1-苯并吡喃-7-基）氧基]乙酸（6c-f，h，n和x）显示出有效的利钠尿和尿尿尿酸活性，而4 -氧代-3-苯基-4H-呋喃[2,3-h] [1]苯并吡喃-8-羧酸（6dd）仅具有强大的利尿活性。还讨论了结构-活性关系。
• Identification of potent and selective small molecule inhibitors of the cation channel TRPM4
  作者：Lijo Cherian Ozhathil、Clémence Delalande、Beatrice Bianchi、Gabor Nemeth、Sven Kappel、Urs Thomet、Daniela Ross-Kaschitza、Céline Simonin、Matthias Rubin、Jürg Gertsch、Martin Lochner、Christine Peinelt、Jean-Louis Reymond、Hugues Abriel

  DOI：10.1111/bph.14220

  日期：2018.6

  and has not yet been validated as a therapeutic target due to the lack of potent and selective inhibitors. We sought to discover a novel series of small-molecule inhibitors by combining in silico methods and cell-based screening assay, with sub-micromolar potency and improved selectivity from previously reported TRPM4 inhibitors. EXPERIMENTAL APPROACH Here, we developed a high throughput screening compatible

  背景和目的 TRPM4 是一种钙激活的非选择性阳离子通道，在许多组织中表达，与多种疾病有关，由于缺乏有效的选择性抑制剂，尚未被验证为治疗靶点。我们试图通过结合计算机方法和基于细胞的筛选测定来发现一系列新型小分子抑制剂，其具有亚微摩尔效力，并且比之前报道的 TRPM4 抑制剂具有更高的选择性。实验方法在这里，我们开发了一种高通量筛选兼容测定法，使用 Na+ 敏感染料记录细胞中 TRPM4 介导的 Na+ 流入，并使用该测定法筛选通过使用先前已知的弱活性的基于配体的虚拟筛选选择的一小组化合物和非选择性 TRPM4 抑制剂作为种子分子。使用常规电生理学方法来验证命中化合物在过表达 TRPM4 的 HEK293 细胞和内源表达前列腺癌细胞系 LNCaP 中的效力和选择性。使用蛋白质印迹和电生理学实验研究了化合物 5 的化学伴侣特性。主要结果 一系列卤代邻氨基苯甲酰胺被鉴定为具有 TRPM4 抑制特
• [EN] NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS UTILES EN TANT QU'INHIBITEURS DE S100
  申请人：ACTIVE BIOTECH AB

  公开号：WO2015177367A1

  公开（公告）日：2015-11-26

  A compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.

  式（I）的化合物或其药用盐以及包含该化合物的药物组合物。该化合物是S100A9与相互作用伙伴（如RAGE、TLR4和EMMPRIN）之间相互作用的抑制剂，因此在治疗癌症、自身免疫性疾病、炎症性疾病和神经退行性疾病等疾病方面是有用的。
• Monoamine re-uptake inhibiting 1-[2-[(phenoxyphenyl)methoxy]ethyl]- piperazines as potential antidepressants
  作者：J. Wieringa、A. van den Meerendonk、J. Steenvoorden、G. Heeres、F. van Bakel、T. Roeters、R. van der Hulst、A. Den Blanken、D. Leysen、R. Plate、Th. de Boer、H. Rijk

  DOI：10.1002/recl.19931120212

  日期：——

  A series of 1-[2-[(2-phenoxyphenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines 17–50 (Figure 1) were prepared and tested as inhibitors of biogenic amine re-uptake. In our search for antidepressants, the relationship between their in vitro and in vivo activity as dopamine-reuptake inhibitors is described quantitatively by using Retention Index values determined by reversed-phase liquid chromatography

  一系列的1- [2 - [（2-苯氧基苯基）甲氧基]乙基] -4-（3-苯基丙基）哌嗪17-50（图1）的制备和作为生物胺再摄取抑制剂的测试。在我们的抗抑郁药的搜索，它们之间的关系的体外和体内活性的多巴胺再摄取抑制剂是通过使用反相液相色谱法测定保留指数值定量描述。
• Chemical Modulation of the 1-(Piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazole-2-one Scaffold as a Novel NLRP3 Inhibitor
  作者：Simone Gastaldi、Valentina Boscaro、Eleonora Gianquinto、Christina F. Sandall、Marta Giorgis、Elisabetta Marini、Federica Blua、Margherita Gallicchio、Francesca Spyrakis、Justin A. MacDonald、Massimo Bertinaria

  DOI：10.3390/molecules26133975

  日期：——

  In the search for new chemical scaffolds able to afford NLRP3 inflammasome inhibitors, we used a pharmacophore-hybridization strategy by combining the structure of the acrylic acid derivative INF39 with the 1-(piperidin-4-yl)1,3-dihydro-2H-benzo[d]imidazole-2-one substructure present in HS203873, a recently identified NLRP3 binder. A series of differently modulated benzo[d]imidazole-2-one derivatives

  在寻找能够提供 NLRP3 炎症小体抑制剂的新化学支架时，我们使用了药效团杂交策略，将丙烯酸衍生物 INF39 的结构与 1-(piperidin-4-yl)1,3-dihydro-2 H -benzo[d]imidazole-2-one 亚结构存在于 HS203873 中，这是一种最近发现的 NLRP3 粘合剂。设计并合成了一系列不同调制的苯并 [d] 咪唑-2-one 衍生物。获得的化合物在体外进行筛选，以测试它们抑制 LPS/ATP 刺激的 PMA 分化的 THP-1 细胞中 NLRP3 依赖性细胞焦亡和 IL-1β 释放的能力。使用新开发的测定法评估所选化合物降低人重组 NLRP3 ATPase 活性的能力。从该筛选中，化合物9、13和18能够浓度依赖性地抑制 LPS/ATP 刺激的人类巨噬细胞中 IL-1β 的释放，成为该系列中最有前途的 NLRP3 抑制剂。计算模拟用于构建 NLRP3